Tandem Diabetes Care Inc TNDM
We take great care to ensure that the data presented and summarized in this overview for TANDEM DIABETES CARE INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TNDM
View all-
Black Rock Inc. New York, NY11.1MShares$381 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.36MShares$252 Million0.01% of portfolio
-
Capital World Investors Los Angeles, CA3.27MShares$112 Million0.02% of portfolio
-
State Street Corp Boston, MA2.66MShares$90.9 Million0.0% of portfolio
-
Arrow Mark Colorado Holdings LLC Denver, CO2.39MShares$81.7 Million1.44% of portfolio
-
Fred Alger Management, LLC New York, NY1.98MShares$67.7 Million0.42% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.85MShares$63.4 Million1.32% of portfolio
-
Gw&K Investment Management, LLC Boston, MA1.8MShares$61.6 Million0.65% of portfolio
-
Jennison Associates LLC1.78MShares$61 Million0.05% of portfolio
-
Geode Capital Management, LLC Boston, MA1.53MShares$52.2 Million0.01% of portfolio
Latest Institutional Activity in TNDM
Top Purchases
Top Sells
About TNDM
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Insider Transactions at TNDM
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 16
2024
|
Rick Carpenter Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
145
-0.96%
|
$4,640
$32.66 P/Share
|
Dec 16
2024
|
Rick Carpenter Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
406
+2.62%
|
-
|
Dec 16
2024
|
Mark David Novara EVP & CHIEF COMMERCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
10,732
-35.55%
|
$343,424
$32.66 P/Share
|
Dec 16
2024
|
Mark David Novara EVP & CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
29,658
+49.56%
|
-
|
Nov 21
2024
|
Kim D Blickenstaff Director |
SELL
Open market or private sale
|
Indirect |
30,000
-15.37%
|
$930,000
$31.38 P/Share
|
Nov 20
2024
|
Kim D Blickenstaff Director |
SELL
Open market or private sale
|
Indirect |
10,000
-4.87%
|
$300,000
$30.0 P/Share
|
Nov 15
2024
|
Elizabeth Anne Gasser EVP, Chief Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
619
+17.16%
|
$9,285
$15.64 P/Share
|
Nov 15
2024
|
Elizabeth Anne Gasser EVP, Chief Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,145
-13.82%
|
$30,915
$27.34 P/Share
|
Nov 15
2024
|
Elizabeth Anne Gasser EVP, Chief Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,140
+18.74%
|
-
|
Nov 15
2024
|
John F Sheridan PRESIDENT & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
381
+0.7%
|
$5,715
$15.64 P/Share
|
Nov 15
2024
|
John F Sheridan PRESIDENT & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,309
-2.62%
|
$116,343
$27.34 P/Share
|
Nov 15
2024
|
John F Sheridan PRESIDENT & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
8,499
+4.81%
|
-
|
Nov 15
2024
|
Leigh Vosseller EVP & CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
765
-1.18%
|
$20,655
$27.34 P/Share
|
Nov 15
2024
|
Leigh Vosseller EVP & CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,140
+3.13%
|
-
|
Nov 15
2024
|
Shannon Marie Hansen EVP & Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
561
+4.65%
|
$8,415
$15.64 P/Share
|
Nov 15
2024
|
Shannon Marie Hansen EVP & Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
703
-3.17%
|
$18,981
$27.34 P/Share
|
Nov 15
2024
|
Shannon Marie Hansen EVP & Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,967
+8.04%
|
-
|
Nov 15
2024
|
Susan Morrison EVP & Chief Admin. Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
613
-0.82%
|
$16,551
$27.34 P/Share
|
Nov 15
2024
|
Susan Morrison EVP & Chief Admin. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,140
+2.74%
|
-
|
Nov 15
2024
|
Rick Carpenter Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
563
+3.7%
|
$8,445
$15.64 P/Share
|
Last 12 Months Summary
Exercise of conversion of derivative security | 191K shares |
---|---|
Grant, award, or other acquisition | 8.82K shares |
Other acquisition or disposition | 21.1K shares |
Open market or private purchase | 532 shares |
Payment of exercise price or tax liability | 57.6K shares |
---|---|
Other acquisition or disposition | 21.1K shares |
Bona fide gift | 8.53K shares |
Open market or private sale | 45K shares |